Premium
Positivity and incidence of human papillomavirus in women attending gynecological department of a major comprehensive hospital in Kunming, China 2012–2014
Author(s) -
Zou Huachun,
Sun Yi,
Zhang Guiqian,
Tu Yuanquan,
Meng Xiaojun,
Liu Tieniu,
Ping Zhuxian,
Fan Xin,
Gao Yuhong
Publication year - 2016
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.24377
Subject(s) - medicine , incidence (geometry) , human papillomavirus , hpv infection , cervical cancer , obstetrics , gynecology , demography , cancer , physics , optics , sociology
HPV DNA testing is receiving increasing popularity in cervical cancer screening. There is a lack of universal guidelines on HPV testing. Our study aimed to assess age‐specific and year‐on‐year trend of HPV positivity and incidence and HPV retesting among 26,457 individual women attending the gynecological department at the First People's Hospital of Yunnan Province (FPHY) who had an HPV testing between January 1, 2012 and December 31, 2014. HPV 16, HPV 52, and cp8304 ranked among top 5 with regard to positivity in each year and overall incidence. The positivity of various HPV types peaked among women aged 15–19 years, then sharply decreased with age, stabilized among women aged 25–49 years and then surged again among women aged 50 years and older. The positivity of high‐risk (HR) HPV types, including HPV 16, 18, 31, 33, 56 and 58, were on the rise during the time period ( P < 0.05 for all). HR HPV types tended to be more likely to persist than LR HPV types ( P < 0.05). Additionally, the incidence rate for any HR HPV type was also significantly higher than that for any LR HPV type (42.8 vs. 12.6 per 100 person‐years, P < 0.001). The majority (57.3–77.5%) of women detected with HR HPV types did not retest within 12 months. Clinical guidelines on HPV DNA testing are needed and education, and counseling about HPV infection and its implications for women detected with HPV at clinical settings, are warranted. J. Med. Virol. 88:703–711, 2016 . © 2015 Wiley Periodicals, Inc.